Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: J Control Release. 2022 Jan 22;343:267–276. doi: 10.1016/j.jconrel.2022.01.024

Figure 7: Combination of 131I-ELP and ELP-K12/CpG significantly inhibits tumor growth and extends mouse survival.

Figure 7:

(A) Average size of 4T1 tumors untreated or treated with 131I-ELP monotherapy, CpG monotherapy, ELP-K12/CpG monotherapy, or a combination of 131I-ELP and ELP-K12/CpG. CpG alone or in complex with ELP-K12 was administered i.t. at a dose of 100 μg; for combination therapy 131I-ELP was administered intratumorally one day later at a dose of 122.1 kBq/mm 3. The same radioactivity dose was used for 131I-ELP monotherapy. *p<0.05 (ANOVA, Tukey). (B) Kaplan-Meier survival curves for treatment groups (n=8–9). **p<0.05 (Mantel-Cox test)